Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPREDICT: 89Zr-crefmirlimab berdoxam PET/CT in Advanced Malignancies
NCT05013099Phase 2Active, not recruiting
- Sponsor
- ImaginAb
- Start
- Dec 2021
- Primary completion
- Jul 2025
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 2 trial of zirconium-89 crefmirlimab berdoxam in melanoma, Merkel cell carcinoma (MCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), sponsored by ImaginAb. Started Dec 2021; status: active, not recruiting.
02
Drugs
zirconium-89 crefmirlimab berdoxam
03
Conditions
melanomaMerkel cell carcinoma (MCC)renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05013099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013099.